Early Routine Bowel Preparation for Suspected Acute Diverticular Bleeding
1 other identifier
interventional
415
1 country
1
Brief Summary
This investigation will utilize both a five-year retrospective analysis and a two-year prospective investigation. Variables including age; gender; presence of anticoagulation medication; hospital length of stay; total transfused red blood cell units; presence of heart failure, chronic kidney disease, or lung disease; history of diverticular disease; whether colonoscopy was performed; if therapeutic hemostasis was performed during colonoscopy; and information regarding prior colonoscopies in the past 10 years will be collected for analysis. A small number of early bowel preparation patients are expected in the retrospective study; therefore, a prospective study occurring over the next 12 months will be conducted. Patients agreeing to participate in the study would have a four-liter dose of PEG 3350 ordered, and the medication would be delivered within the first 24 hours of hospitalization. Radiographic studies including computed tomography angiography, tagged RBC scan, and angiography will not be obtained in the first 24 hours of hospital admission and be considered only if the patient has ongoing hematochezia at the completion of their bowel preparation. After completion of the 12-month investigative period (or earlier if sufficient sample size is obtained for clinical significance), data will be analyzed for dissemination consideration.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Mar 2023
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 22, 2020
CompletedFirst Posted
Study publicly available on registry
December 28, 2021
CompletedStudy Start
First participant enrolled
March 28, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2024
CompletedMarch 31, 2023
March 1, 2023
1.1 years
September 22, 2020
March 30, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Hospital length of stay
Hospital length of stay in the early bowel preparation, late bowel preparation, and no bowel preparation groups.
5 years of data will be collected
Secondary Outcomes (4)
Units of RBC transfused
5 years of data will be collected
Colonoscopy details
5 years of data will be collected
Therapeutic Hemostasis Invervention
After discharge
Radiographic Studies
5 years of data will be collected
Study Arms (2)
Retrospective Cohort
NO INTERVENTIONColonoscopy was performed, either early bowel preparation, late bowel preparation or no bowel preparation patients.
Prospective Cohort
EXPERIMENTALEarly bowel preparation for colonoscopy patients
Interventions
Early (\<24 hours) bowel cleansing prior to colonoscopy.
Eligibility Criteria
You may qualify if:
- Patient admitted to Methodist Dallas Medical Center
- Age greater than 18 years
- Patient evaluated by gastroenterology consult service during admission
- Hospitalization with diagnosis of "hematochezia", "acute gastrointestinal bleeding", "acute blood loss anemia", or "anemia"
- Endorsed or witnessed episode of painless hematochezia
- Patients exhibiting hemodynamic stability (heart rate \<110; systolic blood pressure \>90) after initial evaluation and resuscitation by admitting/emergency room physicians
You may not qualify if:
- Age less than 18 years
- Persistent hypotension despite initial intravenous fluid resuscitation or fever
- Bowel preparation started 24 hours after initial presentation
- Documented symptoms of dysphagia or odynophagia
- Signs or symptoms suggestive of gastrointestinal obstruction (or ileus) on initial presentation (e.g., abdominal pain, nausea and/or vomiting)
- Inability to complete bowel preparation
- Personal history of inflammatory bowel disease or cirrhosis
- History of immunosuppression (e.g., AIDS, immunosuppressive medication)
- Personal history of colon cancer
- Prior gastric bypass, small bowel, or colonic resection
- Stool culture positive for tested organisms to include Clostridium difficile
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Methodist Dallas Medical Center
Dallas, Texas, 75203, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Prashant Kedia, MD
The Methodist Hospital Research Institute
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 22, 2020
First Posted
December 28, 2021
Study Start
March 28, 2023
Primary Completion
May 1, 2024
Study Completion
May 1, 2024
Last Updated
March 31, 2023
Record last verified: 2023-03